Skip to Main Content

Eli Lilly

Eli Lilly is a top producer of insulin and antibiotics, and a growing force in weight loss drugs and treatments for Alzheimer’s. The company is also known for drugs to treat diabetes (Trulicity, Humalog) and depression (Prozac, Cymbalta).

Latest

Biotech Elaine Chen

STAT Plus: 3 trends to watch in biotech in 2025

Biotech Elaine Chen

STAT Plus: Eli Lilly’s obesity drug Zepbound approved to treat sleep apnea in U.S.

Pharma Elaine Chen

STAT Plus: What Novo Nordisk’s disappointing trial results mean for the obesity drug market

Pharma Elaine Chen, Katie Palmer, Ed Silverman, and Lizzy Lawrence

STAT Plus: FDA confirms shortage of weight loss drug tirzepatide is over, gives compounders a grace period

Adam's Take Adam Feuerstein

STAT Plus: Who stood out as Best Biopharma CEO of 2024?

The Readout LOUD Elaine Chen, Allison DeAngelis, and Adam Feuerstein

The pharma industry’s silence on RFK Jr., and efforts by parents to develop gene therapies for their children

Pharma Elaine Chen and Katie Palmer

STAT Plus: Eli Lilly strikes Zepbound deal with Ro, amid questions about future of compounded GLP-1s

Biotech Elaine Chen

STAT Plus: Eli Lilly to test obesity medications as treatments for alcohol and drug addiction, CEO says

All Coverage

The Readout LOUD Allison DeAngelis, Adam Feuerstein, and Elaine Chen

Lilly’s earnings surprise, investors mull the election, & a spooky ghost story

Biotech Elaine Chen

STAT Plus: Eli Lilly says modified dosing of its Alzheimer’s drug may be safer

advertisement

Pharmalot Lizzy Lawrence, Elaine Chen, and Ed Silverman

STAT Plus: Eli Lilly weight loss drug shortage underscores deeper issues with FDA oversight

Pharmalot Ed Silverman

STAT Plus: Catalent tries to reassure customers about its deal with Novo Holdings

The Readout LOUD Elaine Chen, Adam Feuerstein, and Allison DeAngelis

Biotech’s next gold rush, GLP-1 shortages, and STAT Summit highlights

Pharma Katie Palmer

STAT Plus: In stark reversal, FDA to reconsider removal of Eli Lilly weight loss drug from shortage list

Health Elaine Chen

STAT Plus: As Eli Lilly, compounders battle over weight loss drugs, patients are caught in the middle

Politics John Wilkerson

STAT Plus: Medicare already covers GLP-1s for half of seniors with obesity, new report finds

Health tech Brittany Trang

STAT Plus: Eli Lilly, Insitro ink a new kind of AI drug development deal

Health Elaine Chen and Allison DeAngelis

STAT Plus: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target

Pharma Andrew Joseph

STAT Plus: At major cardiology conference, Wegovy’s the word

The Readout LOUD Allison DeAngelis, Elaine Chen, and Adam Feuerstein

Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy

Morning Rounds Theresa Gaffney

Is the GLP-1 party running down for Hims, and a study for the weekend

Health tech Katie Palmer and Nicholas Florko

STAT Plus: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?

Biotech Elaine Chen

STAT Plus: Eli Lilly’s lauded discount of its obesity drug Zepbound comes with caveats

Biotech Elaine Chen

STAT Plus: Lilly launches Zepbound vials in move that could ease supply constraints

Pharmalot Ed Silverman

STAT Plus: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?

Biotech Matthew Herper

STAT Plus: Eli Lilly’s billions: Can the world’s most valuable pharma company keep inventing drugs at this pace?

Biotech Elaine Chen

STAT Plus: Eli Lilly boosts 2024 revenue guidance by $3 billion on Mounjaro, Zepbound sales

Biotech Elaine Chen and Andrew Joseph

STAT Plus: Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data

Pharmalot Ed Silverman

STAT Plus: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs